Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Affy, Sigma-Aldrich Among Vendors to Occupy New Nasdaq Tier

NEW YORK, June 28 (GenomeWeb News) - Shares of Qiagen, Affymetrix, Invitrogen, Molecular Devices, Serologicals, and Sigma-Aldrich will be listed on the Nasdaq Global Select Market when the exchange creates the market tier for a set of high-performing companies on July 1, according to the Nasdaq web site.

 

On Feb. 15 Nasdaq said it will rename its National Market to Nasdaq Global Market and create a Nasdaq Global Select Market with the highest initial listing standards of any exchange in the world.

 

Under the change, companies listed on the exchange will be classified under three listing tiers: Nasdaq Global Select Market, Nasdaq Global Market, and Nasdaq Capital Market. Nasdaq said it plans to launch indexes based on these new tiers.

 

The financial and liquidity requirements to be listed on the Global Select Market are available here.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.